eTheRNA immunotherapies, the mRNA immunotherapy company, has appointed Ulrich Platte as the company's new CFO. Ulrich will join the company on 3 June 2019.
Ulrich has a broad experience acquired over the last 20 years in different industries including the life sciences, medical device and pharmaceutical sectors. He has held progressively senior positions in financial management roles, including previous CFO roles, and his operational experience encompasses corporate finance, group financial control, strategic planning and M&A.
Latterly Ulrich has been engaged in a number of early-stage companies in the life science sector supporting financing and business development activities. He is a graduate in business administration and holds an MBA from the University of Chicago.
Steven Powell, CEO of eTheRNA, said: "I am delighted to welcome Ulrich to the company. He has extensive financial leadership skills and experience in the sector, which will be of great benefit to eTheRNA. We are at an exciting stage of the company's development and Ulrich's business experience in international commercial and large-scale research and development organisations will assist the Board and management team in delivering both our strategic and R&D objectives."
